Background
Glioblastoma multiforme (GBM) is a highly aggressive primary brain tumor with limited therapeutic options and poor prognosis. Advances in molecular profiling have identified numerous potential targets, yet many remain underexplored. UniProt entry P42336 corresponds to a human protein implicated in cellular processes relevant to cancer biology but has not been extensively studied in GBM. Preliminary expression data suggest altered regulation of P42336 in GBM tissues, positioning it as a putative target that warrants further experimental validation to clarify its role and therapeutic potential.
Data-mining rationale
To identify novel molecular candidates in GBM, we cross-referenced reviewed human protein entries from UniProt annotated with "glioblastoma multiforme" against 724 microarray datasets from the NCBI Gene Expression Omnibus (GEO). UniProt:P42336 consistently appeared in multiple GBM-related expression profiling datasets (GDS:200317497, GDS:200273558, GDS:200320501, GDS:200318047, and GDS:200318046), indicating differential expression patterns in tumor versus normal brain tissues or among GBM subtypes. Despite this, no clinical development programs targeting P42336 were identified, highlighting a translational gap that merits further investigation.
Why prior analyses may have missed this
Many of the GEO datasets including P42336 predate the adoption of modern empirical-Bayes statistical methods such as limma, which enhance detection of differentially expressed genes by improving variance estimation and controlling false discovery rates. Earlier analyses may have lacked sufficient statistical power or appropriate multiple-testing correction, potentially overlooking subtle but biologically meaningful expression changes of P42336. Additionally, heterogeneity in patient samples and limited cohort sizes may have contributed to inconsistent findings. Re-analysis with updated bioinformatics approaches could better define the significance of P42336 expression alterations in GBM.
Reasoning for further validation
Given the putative association of P42336 with GBM expression profiles and the absence of clinical targeting efforts, several experimental steps are recommended:
- Re-analyze the identified GEO datasets using limma with Benjamini-Hochberg false discovery rate correction (FDR < 0.05) to robustly assess differential expression of P42336.
- Validate expression changes by quantitative PCR (qPCR) in independent GBM patient cohorts to confirm reproducibility.
- Examine tissue specificity and expression patterns of P42336 in normal and tumor tissues using resources such as GTEx and the Human Protein Atlas to understand biological context and potential off-target effects.
- Utilize protein interaction and pathway analysis tools like STRING and OmniPath to elucidate molecular networks involving P42336, which may reveal mechanistic insights or synergistic targets.
- If validation supports a functional role in GBM, assess druggability through databases such as DGIdb and ChEMBL to identify existing compounds or guide novel therapeutic development.
This integrative approach will help determine whether P42336 represents a viable molecular target for future translational research in glioblastoma multiforme.